title: Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.
abstract: OBJECTIVE
  Increases in brain cyclooxygenase-2 (COX2) are associated with the central inflammatory response and with delayed neuronal death, events that cause secondary insults after traumatic brain injury. A growing literature supports the benefit of COX2-specific inhibitors in treating brain injuries.
  
  
  METHODS
  DFU [5,5-dimethyl-3(3-fluorophenyl)-4(4-methylsulfonyl)phenyl-2(5)H)-furanone] is a third-generation, highly specific COX2 enzyme inhibitor. DFU treatments (1 or 10 mg/kg intraperitoneally, twice daily for 3 d) were initiated either before or after traumatic brain injury in a lateral cortical contusion rat model.
  
  
  RESULTS
  DFU treatments initiated 10 minutes before injury or up to 6 hours after injury enhanced functional recovery at 3 days compared with vehicle-treated controls. Significant improvements in neurological reflexes and memory were observed. DFU initiated 10 minutes before injury improved histopathology and altered eicosanoid profiles in the brain. DFU 1 mg/kg reduced the rise in prostaglandin E2 in the brain at 24 hours after injury. DFU 10 mg/kg attenuated injury-induced COX2 immunoreactivity in the cortex (24 and 72 h) and hippocampus (6 and 72 h). This treatment also decreased the total number of activated caspase-3-immunoreactive cells in the injured cortex and hippocampus, significantly reducing the number of activated caspase-3-immunoreactive neurons at 72 hours after injury. DFU 1 mg/kg amplified potentially anti-inflammatory epoxyeicosatrienoic acid levels by more than fourfold in the injured brain. DFU 10 mg/kg protected the levels of 2-arachidonoyl glycerol, a neuroprotective endocannabinoid, in the injured brain.
  
  
  CONCLUSIONS
  These improvements, particularly when treatment began up to 6 hours after injury, suggest exciting neuroprotective potential for COX2 inhibitors in the treatment of traumatic brain injury and support the consideration of Phase I/II clinical trials.
authors.affiliation: Department of Neurosurgery, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
authors.forename: Jonas J
authors.initials: JJ
authors.lastname: Gopez
authors.forename: Hongfei
authors.initials: H
authors.lastname: Yue
authors.forename: Ram
authors.initials: R
authors.lastname: Vasudevan
authors.forename: Amir S
authors.initials: AS
authors.lastname: Malik
authors.forename: Lester N
authors.initials: LN
authors.lastname: Fogelsanger
authors.forename: Shawn
authors.initials: S
authors.lastname: Lewis
authors.forename: David
authors.initials: D
authors.lastname: Panikashvili
authors.forename: Esther
authors.initials: E
authors.lastname: Shohami
authors.forename: Susan A
authors.initials: SA
authors.lastname: Jansen
authors.forename: Raj K
authors.initials: RK
authors.lastname: Narayan
authors.forename: Kenneth I
authors.initials: KI
authors.lastname: Strauss
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001095:Arachidonic Acids / Q000032:analysis; D001259:Ataxia / Q000188:drug therapy / Q000209:etiology; D001923:Brain Chemistry; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D051546:Cyclooxygenase 2; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015232:Dinoprostone / Q000032:analysis; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D015777:Eicosanoids / Q000032:analysis; D063388:Endocannabinoids; D004790:Enzyme Induction; D005106:Exploratory Behavior / Q000187:drug effects; D005663:Furans / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005989:Glycerides / Q000032:analysis; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011292:Premedication; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D012021:Reflex, Abnormal / Q000187:drug effects
chemical_list: C106876:5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D015777:Eicosanoids; D063388:Endocannabinoids; D005663:Furans; D005989:Glycerides; D018696:Neuroprotective Agents; C094503:glyceryl 2-arachidonate; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C489691:Ptgs2 protein, rat; D015232:Dinoprostone
references.citation: Neurosurgery. 1999 Jun;44(6):1286-98
references.pmid: 10371629
references.citation: J Biol Chem. 1996 Oct 4;271(40):24794-9
references.pmid: 8798751
references.citation: Biochem Biophys Res Commun. 2000 Jun 16;272(3):744-8
references.pmid: 10860826
references.citation: J Neurochem. 1991 Sep;57(3):860-9
references.pmid: 1677678
references.citation: J Neurotrauma. 2000 Apr;17(4):283-98
references.pmid: 10776913
references.citation: Nature. 2001 Oct 4;413(6855):527-31
references.pmid: 11586361
references.citation: J Neuroimmunol. 2001 Dec 3;121(1-2):76-8
references.pmid: 11730942
references.citation: J Neurotrauma. 2000 Aug;17(8):695-711
references.pmid: 10972245
references.citation: J Neurosci. 1997 Sep 15;17(18):7166-79
references.pmid: 9278551
references.citation: Biochem Biophys Res Commun. 1999 Jan 19;254(2):446-9
references.pmid: 9918858
references.citation: Neuroreport. 1998 Mar 30;9(5):783-6
references.pmid: 9579665
references.citation: J Pharmacol Exp Ther. 1999 Aug;290(2):551-60
references.pmid: 10411562
references.citation: J Pharmacol Exp Ther. 2000 May;293(2):417-25
references.pmid: 10773011
references.citation: Brain Res. 2004 May 8;1007(1-2):98-108
references.pmid: 15064140
references.citation: J Biol Chem. 1988 Feb 25;263(6):3022-8
references.pmid: 3125173
references.citation: BMJ. 1997 Jun 28;314(7098):1855-9
references.pmid: 9224126
references.citation: J Neurochem. 1996 Jan;66(1):6-13
references.pmid: 8522990
references.citation: J Neurochem. 2001 Sep;78(6):1297-306
references.pmid: 11579138
references.citation: Neuron. 1993 Aug;11(2):371-86
references.pmid: 8352945
references.citation: J Neurosci. 2002 Jan 1;22(1):257-64
references.pmid: 11756509
references.citation: Neuroscience. 1989;28(1):233-44
references.pmid: 2761692
references.citation: Eur J Neurosci. 2001 Feb;13(3):569-75
references.pmid: 11168565
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10954-9
references.pmid: 9724811
references.citation: J Neurosci. 1998 Aug 1;18(15):5663-72
references.pmid: 9671657
references.citation: J Cereb Blood Flow Metab. 1988 Jun;8(3):395-402
references.pmid: 3366801
references.citation: J Biol Chem. 1990 Oct 5;265(28):16737-40
references.pmid: 2120205
references.citation: Acta Neuropathol. 2002 Feb;103(2):157-62
references.pmid: 11810182
references.citation: Proc Natl Acad Sci U S A. 1992 May 1;89(9):3917-21
references.pmid: 1570314
references.citation: Neurosci Lett. 2002 Jan 11;317(2):61-4
references.pmid: 11755240
references.citation: J Cereb Blood Flow Metab. 1996 Nov;16(6):1366-72
references.pmid: 8898713
references.citation: J Neurotrauma. 1998 Dec;15(12):1005-13
references.pmid: 9872457
references.citation: J Neurotrauma. 2002 Jan;19(1):1-15
references.pmid: 11852973
references.citation: Proc Natl Acad Sci U S A. 1989 Mar;86(5):1657-61
references.pmid: 2493647
references.citation: J Neurotrauma. 1989 Summer;6(1):31-7
references.pmid: 2502634
references.citation: Biochem Biophys Res Commun. 1997 Jun 18;235(2):374-6
references.pmid: 9199200
references.citation: Am J Physiol. 1999 Apr;276(4 Pt 2):H1369-78
references.pmid: 10199864
references.citation: Exp Brain Res. 2002 Nov;147(2):193-9
references.pmid: 12410334
references.citation: Surg Neurol. 1999 Sep;52(3):238-45
references.pmid: 10511080
references.citation: Crit Rev Neurobiol. 1999;13(1):45-82
references.pmid: 10223523
references.citation: J Neuroimmunol. 1997 Jun;76(1-2):193-205
references.pmid: 9184651
references.citation: J Neurochem. 1984 Jul;43(1):71-82
references.pmid: 6427411
references.citation: Biochim Biophys Acta. 1994 May 13;1212(2):217-24
references.pmid: 7514040
references.citation: J Neurosci. 2002 May 1;22(9):3504-11
references.pmid: 11978827
references.citation: Acta Neurochir Suppl. 1997;70:12-6
references.pmid: 9416264
references.citation: J Biol Chem. 2000 Oct 27;275(43):33744-9
references.pmid: 10931854
references.citation: Neuroreport. 1995 Jan 26;6(2):245-8
references.pmid: 7756602
references.citation: Inflamm Res. 1996 Feb;45(2):68-74
references.pmid: 8907587
references.citation: Neuroscience. 2003;117(4):909-19
references.pmid: 12654342
references.citation: Bioorg Med Chem Lett. 1999 Nov 15;9(22):3181-6
references.pmid: 10576684
references.citation: J Neurotrauma. 1997 Jun;14(6):399-408
references.pmid: 9219854
references.citation: Neurosurgery. 1992 Jan;30(1):17-22
references.pmid: 1738450
references.citation: Biochem Pharmacol. 1995 Jun 29;50(1):83-90
references.pmid: 7605349
references.citation: Br J Pharmacol. 1997 May;121(1):105-17
references.pmid: 9146894
references.citation: J Neurochem. 1981 Oct;37(4):892-6
references.pmid: 6798171
references.citation: Mol Pharmacol. 1994 Feb;45(2):245-54
references.pmid: 8114674
references.citation: Biochem J. 1997 Sep 1;326 ( Pt 2):593-9
references.pmid: 9291137
references.citation: J Neurosci. 1998 Jul 1;18(13):4914-28
references.pmid: 9634557
references.citation: Anesth Analg. 1998 Apr;86(4):759-65
references.pmid: 9539598
references.citation: Neurology. 2002 Apr 23;58(8):1277-9
references.pmid: 11971099
references.citation: J Neurochem. 2001 Feb;76(3):855-64
references.pmid: 11158257
references.citation: Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12013-7
references.pmid: 7991575
references.citation: Lancet. 2004 Oct 9-15;364(9442):1321-8
references.pmid: 15474134
references.citation: J Mol Neurosci. 1998 Jun;10(3):209-17
references.pmid: 9770643
references.citation: J Neurophysiol. 1997 Jan;77(1):167-76
references.pmid: 9120557
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):267-77
references.pmid: 15063335
references.citation: Eur J Pharmacol. 2002 Oct 25;453(2-3):189-95
references.pmid: 12398903
references.citation: Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401
references.pmid: 11383749
references.citation: J Comp Neurol. 2001 May 7;433(3):299-311
references.pmid: 11298357
references.citation: J Neurotrauma. 2002 May;19(5):627-38
references.pmid: 12042097
references.citation: Cerebrovasc Brain Metab Rev. 1994 Summer;6(2):109-62
references.pmid: 7915532
references.citation: Br J Anaesth. 1997 May;78(5):520-3
references.pmid: 9175965
references.citation: J Neurosurg. 1995 Oct;83(4):627-30
references.pmid: 7674011
references.citation: Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8721-6
references.pmid: 10411942
references.citation: J Neurosci. 1998 Jan 1;18(1):26-35
references.pmid: 9412483
references.citation: Am J Pathol. 1999 Sep;155(3):995-1004
references.pmid: 10487857
references.citation: J Neurotrauma. 2003 May;20(5):463-76
references.pmid: 12803978
references.citation: J Comp Neurol. 1996 Dec 16;376(3):447-62
references.pmid: 8956110
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5292-7
references.pmid: 10220459
references.citation: J Clin Invest. 1995 Apr;95(4):1669-75
references.pmid: 7706475
references.citation: J Cereb Blood Flow Metab. 1987 Feb;7(1):58-63
references.pmid: 3468118
references.citation: Eur J Pharmacol. 1998 Oct 16;359(1):1-18
references.pmid: 9831287
references.citation: J Lipid Res. 2000 Jun;41(6):873-81
references.pmid: 10828079
references.citation: J Neurochem. 2000 Sep;75(3):1264-73
references.pmid: 10936210
references.citation: J Neurotrauma. 1992 Spring;9(1):11-20
references.pmid: 1619672
references.citation: Methods Mol Biol. 1999;120:55-66
references.pmid: 10343310
references.citation: J Neurotrauma. 2002 May;19(5):503-57
references.pmid: 12042091
references.citation: Am J Pathol. 1995 Dec;147(6):1575-83
references.pmid: 7495282
references.citation: Eur J Pharmacol. 1997 May 30;327(2-3):221-5
references.pmid: 9200563
references.citation: Nature. 1994 Jan 20;367(6460):215-6
references.pmid: 8121485
references.citation: Science. 1992 Dec 18;258(5090):1946-9
references.pmid: 1470919
references.citation: Inflamm Res. 1999 Jan;48(1):1-4
references.pmid: 9987677
references.citation: Adv Exp Med Biol. 1992;318:41-56
references.pmid: 1636506
references.citation: Exp Neurol. 1997 Apr;144(2):339-49
references.pmid: 9168834
references.citation: J Neurotrauma. 2000 Jan;17(1):69-81
references.pmid: 10674759
references.citation: J Biol Chem. 1993 Mar 25;268(9):6610-4
references.pmid: 8454631
references.citation: Chin J Traumatol. 2002 Aug;5(4):250-3
references.pmid: 12162906
references.citation: J Neurosci Methods. 1991 Oct;39(3):253-62
references.pmid: 1787745
references.citation: J Neurotrauma. 1988;5(4):303-13
references.pmid: 3249309
references.citation: Brain Res. 2002 Feb 15;927(2):212-5
references.pmid: 11821016
references.citation: J Biol Chem. 2001 Aug 10;276(32):30072-7
references.pmid: 11402053
references.citation: Biochem Pharmacol. 2003 Mar 15;65(6):979-88
references.pmid: 12623129
references.citation: J Neurosci. 1997 Oct 1;17(19):7415-24
references.pmid: 9295387
references.citation: Science. 1999 Aug 20;285(5431):1276-9
references.pmid: 10455056
references.citation: Microcirculation. 1996 Dec;3(4):379-86
references.pmid: 9086449
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2317-21
references.pmid: 8637870